Huahai Pharmaceutical subsidiary reports positive phase III psoriasis trial results

Zhejiang Huahai Pharmaceutical announced that its subsidiary, Shanghai Huaaotai Biopharmaceutical, through Huabo Biotechnology (Shanghai) Co., Ltd., successfully reached primary and all key secondary efficacy endpoints in a pivotal Phase III clinical trial for HB0017 injection. This multi-center, double-blind, randomized, placebo-controlled study investigated HB0017 for treating moderate to severe plaque psoriasis.

The trial enrolled 408 Chinese patients. Results showed that at week 12, patients achieved PASI 75 (≥75% improvement from baseline PASI score) and sPGA 0/1 (clear or almost clear skin), along with PASI 90 (≥90% improvement from baseline PASI score) for key secondary endpoints. The maintenance treatment regimen is expected to offer the longest dosing interval among comparable products, with sustained and stable efficacy throughout the maintenance period.

HB0017, a self-developed IL-17A monoclonal antibody, also shows promise for ankylosing spondylitis, with Phase II clinical data demonstrating positive efficacy and safety. The company has invested approximately RMB 372,050,000 in the HB0017 injection project to date. Future market entry is subject to regulatory approval, and the competitive landscape may evolve.